Pfizer ADC drug TIVDAK has been fully approved by the US FDA for the treatment of recurrent or metastatic cervical cancer. On May 6th, Zaiding Pharmaceuticals announced on its official WeChat account that its partners Pfizer and Genmab have jointly announced that the US Food and Drug Administration (FDA) has approved the application for a supplemental biological agent license (sBLA) for TIVDAK (tisotumab vector tftv), fully approving its use in the treatment of recurrent or metastatic cervical cancer patients who experience disease progression during or after chemotherapy.